Ultragenyx Pharmaceutical Inc.
UX111
Sanfilippo syndrome type A (MPS IIIA)
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews UX111 for Sanfilippo syndrome type A (MPS IIIA) around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“the BLA was resubmitted in January 2026 and included substantial longer-term data, that were recently presented at the 2026 WORLD Symposium”